Biogen Reports Five-Year ORATORIO Data for Ocrevus in Primary Progressive MS

Biogen today presented five-year follow-up data from the Phase 3 ORATORIO trial evaluating Ocrevus (ocrelizumab) in patients with primary progressive multiple sclerosis. The data showed that Ocrevus maintained significant reductions in disability progression over five years of treatment, with a 24% reduction in the risk of confirmed disability progression compared to placebo.